Merck agreed to acquire a vaccine manufacturing facility in Ireland from WuXi, the Irish Foreign Direct Investment Arm (IDA) announced today. IDA Ireland said the move comes as part of long-term plans in Ireland for Merck Sharp & Dohme (MSD), Merck’s Ireland business. The acquisition of the facility, located in Dundalk, brings an investment of…
PharmaEssentia commits to interferon therapy production amid shortage
PharmaEssentia has reaffirmed its commitment to creating access to critical interferon therapies amid a reported global shortage. The Burlington, Massachusetts-based company noted a recent reported shortage of Pegasys (peginterferon alfa-2a). With concerns growing over drug shortages for other therapies, the company said its established cGMP manufacturing network and patient-focused approach can help it meet the…
Eli Lilly to invest $3B in Wisconsin manufacturing plant expansion
Eli Lilly (NYSE:LLY) announced that it plans to invest $3 billion in the expansion of its manufacturing facility in Kenosha County, Wisconsin. In April, Indianapolis-based Eli Lilly acquired the plant in Pleasant Prairie, Wisconsin, from sterile manufacturer Nexus. The company expects its investment to extend its global parenteral (injectable) product manufacturing network. It aims to…
Novavax sells Czech Republic manufacturing site to Novo Nordisk
Novavax announced today that it signed a definitive agreement to sell a European manufacturing plant to Novo Nordisk for $200 million. The agreement centers around the company’s facility in Bohumil, Czech Republic, about 25 miles outside of Prague. It includes a transfer of assets, including a 150,000-square-foot, state-of-the-art recombinant protein manufacturing facility. That includes support…
Nipro launches new glass vials powered by Stevanato Group’s EZ-fill tech
Nipro PharmaPackaging announced today that it launched new D2F (direct-to-fill) glass vials powered by Stevanato Group technology. The vials feature Stevanato’s EZ-fill technology to offer a high-quality, ready-to-use (RTU) solution. Nipro designed the vials to meet the rigorous standards and increasing requirements of the pharmaceutical industry. D2F vials are washed, depyrogenated, packaged in nest and…
SK Pharmteco invests $260M to expand small molecule, peptide production
SK Pharmteco announced that it expanded its small molecule and peptide production capabilities with a $260 million investment. The Rancho Cordova, California-based CDMO plans to construct a new state-of-the-art facility in Sejong, South Korea. It expects to begin operations at the new plant — the company’s fifth in South Korea — in late 2026. The…
Merck KGaA completes €180M Schnelldorf distribution center expansion
Merck KGaA, Darmstadt, Germany announced that it opened its newly expanded Life Science distribution center in Schnelldorf. The company invested €180 million and added 25,000 square meters in space to the site, nearly doubling its size. It now features a manual down filling operation and additional space for the distribution of products to laboratories and…
Thermo Fisher opens new ultra-cold facility in Europe
Thermo Fisher Scientific announced that it opened a new clinical and commercial ultra-cold facility in the Netherlands. The company aims to expand its clinical trial network in Europe and accelerate the development of advanced therapies. Its new current good manufacturing practice (cGMP) facility in Bleiswijk offers pharmaceutical and biopharma customers tailored, end-to-end support throughout the…
What might Hims & Hers decision to sell compounded semaglutide mean for Big Pharma
Novo Nordisk’s semaglutide achieved explosive sales in 2023. Ozempic alone generated $13,892 million in sales for the year. But now that Hims & Hers has revealed plans to sell compounded semaglutide to the masses, questions arise about how the Dutch pharma giant will respond. 2023 was a banner year for the firm with its diabetes…
TriLink BioTechnologies opens new mRNA manufacturing facility
TriLink BioTechnologies today announced it opened its new cGMP mRNA manufacturing facility. The new 32,000 sq. ft. facility, based in San Diego, is specifically designed for mRNA manufacturing. Using the company’s mRNA manufacturing capabilities, it will support late-phase drug developers from Phase 2 to commercialization. TriLink said the opening is expected to help advance the…